a Research Center of Advanced Technologies in Medicine , Torbat Heydariyeh University of Medical Sciences , Torbat Heydariyeh , Iran.
b Nanotechnology Research Center , Pharmaceutical Technology Institute, Mashhad University of Medical Sciences , Mashhad , Iran.
Artif Cells Nanomed Biotechnol. 2018;46(sup2):587-593. doi: 10.1080/21691401.2018.1464460. Epub 2018 Apr 24.
Chitosan-coated ISCOMATRIX nanoparticles co-administrated with PR8 influenza virus were successfully developed via a lipid film hydration method to evaluate their in vivo immuniadjuvant potential in immunization against influenza. The prepared ISCOMATRIX (ISC) and chitosan-coated ISCOMATRIX (ISC-CIT) showed a particle size of 171 and 233 nm with a zeta potential of -9.47 and +5.65, respectively. Furthermore, ISC-CIT formulations were co-administered with PR8 antigen (PR8-ISC-CIT) and their immunogenicity was investigated after intranasal and intramuscular immunization of BALBc/mice. The PR8-ISC formulation elicited more IFN-γ after intranasal or intramuscular administration compared with PR8-ISC-CIT formulation. In contrast, although PR8-ISC-CIT formulation administered by intranasal route secreted more IFN-γ, it significantly decreased the IgG2a/IgG1 ratio and a less immune response was induced. Altogether, the ISC-adjuvanted influenza PR8 antigen could be considered as a powerful intramuscular antigen delivery system for producing a variety of prophylactic and therapeutic vaccines.
壳聚糖包覆的 ISCOMATRIX 纳米颗粒与 PR8 流感病毒共同给药，通过脂质体薄膜水化法成功开发，用于评估其在流感免疫接种中的体内免疫佐剂潜力。所制备的 ISCOMATRIX（ISC）和壳聚糖包覆的 ISCOMATRIX（ISC-CIT）的粒径分别为 171nm 和 233nm，其 zeta 电位分别为-9.47 和+5.65。此外，ISC-CIT 制剂与 PR8 抗原（PR8-ISC-CIT）共同给药，并在 BALBc/小鼠的鼻腔内和肌肉内免疫后研究其免疫原性。与 PR8-ISC-CIT 制剂相比，PR8-ISC 制剂鼻腔内或肌肉内给药后诱导产生更多的 IFN-γ。相比之下，虽然鼻内途径给药的 PR8-ISC-CIT 制剂分泌更多的 IFN-γ，但它显著降低了 IgG2a/IgG1 比值，诱导的免疫反应减弱。总之，ISC 佐剂的流感 PR8 抗原可被视为一种强大的肌肉内抗原递送系统，可用于生产多种预防性和治疗性疫苗。
